CRESTOR Delivers Superior Efficacy in Achievement of Low LDL-C Targets in New VOYAGER Analysis

Monday 29 August 2011 14:39

- This release is not intended for US and Canadian media

AstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which demonstrated that the possibility of reaching the 100 mg/dL LDL-C goal with statin treatment is dependent upon baseline LDL-C and the choice and dose of statin. CRESTOR(TM) (rosuvastatin) helped more patients reach an LDL-C goal of

Latest News

17:08	GSK Participates in the British Embassy's Re-imagining UK Aging Care Event with a Focus on Enhancing Adult
16:34	Join Polkadot Connect x Bitkub Chain 2024 Event: Uniting Global Blockchain Communities for Networking and
16:54	TSX by Astronize, the latest game project on Bitkub Chain, launches Open Beta today
14:05	SCBX ANNOUNCED FIRST-QUARTER NET PROFIT OF BAHT 11.3 BILLION
14:47	Krungsri and Bangkok University Collaborateto Maximize Learning Potential and Enrich Business Experience
14:25	Bangkok Bank reports a net profit of Baht 10,524 million for the first quarter of 2024
13:50	ACCOMM Group Unveils Global Coaching Mentoring Trends in the AI Age and How to Develop Sustainable Leadership and
13:54	Prime Minister of New Zealand to present the New Zealand Alumni Networking award
13:39	NX Group Invests in Singapore AI Technology Startup SWAT MOBILITY
10:44	BRIDGESTONE TURANZA T005 EV, a Premium High-Performance for EVs with the Cutting-Edge ENLITEN(R) Technology Selected as Original Equipment to Elevate a New EV MG4 XPOWER from